Recipharm is a global CDMO headquartered in Stockholm, Sweden, with development and manufacturing facilities across Europe, North America, and Asia. The company provides end-to-end drug substance and biologics services from discovery through clinical and commercial supply, including generic APIs, custom process and analytical development, GMP manufacturing, and specialized capabilities for controlled substances, cannabinoids, orphan drugs, and bioconjugates. Recipharm also offers integrated RNA and mRNA solutions, encompassing plasmid and RNA GMP manufacturing, lipid nanoparticle (LNP) formulation, advanced therapy medicinal product (ATMP) fill/finish, process development, and analytical testing to support vaccines and therapeutics at all stages.
